Although it trades at a lofty 14x trailing revenue multiple, the company’s solid growth trajectory and expanding market ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended ...

Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 ...

Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing demand. Forecast Busting ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

After Tempus AI’s Q2 earnings release, analysts at Morgan Stanley increased their price target on the stock from $65 to $68.

Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss ...

It marks the second time Tempus AI has received FDA clearance for a cardiovascular product suite.